RecruitingPhase 2NCT07205887
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Studying Central retinal vein occlusion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EyeBiotech Ltd.
- Principal Investigator
- Charles Miller, MD PhDEyeBiotech Ltd.
- Intervention
- EYE103(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- Scottsdale, Arizona, Scottsdale, Arizona, United States
- Scottsdale, AZ, Scottsdale, Arizona, United States
- Glendale, California, Glendale, California, United States
- Glendale, CA, Glendale, California, United States
- Modesto, California, Modesto, California, United States
- Mountain View, California, Mountain View, California, United States
- Sacramento, CA, Sacramento, California, United States
- Sactamento, California, Sacramento, California, United States
- Sacramento, California, Sacramento, California, United States
- Santa Ana, California, Santa Ana, California, United States
- Fort Lauderdale, Florida, Fort Lauderdale, Florida, United States
- Fort Lauderdale, FL, Fort Lauderdale, Florida, United States
- Lemont, Illinois, Lemont, Illinois, United States
- Lemont, IL, Lemont, Illinois, United States
- Hagerstown, Maryland, Hagerstown, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07205887 on ClinicalTrials.govOther trials for Central retinal vein occlusion
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07456826Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsHarrow Inc
- ENROLLING BY INVITATIONNANCT07318428AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and GlaucomaInje University
- RECRUITINGNCT07308639DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.Bayer
- RECRUITINGPHASE2NCT07259928Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein OcclusionAnnexin Pharmaceuticals AB
- RECRUITINGEARLY PHASE1NCT04008121Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein SodiumMediBeacon
- RECRUITINGNCT07550777Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal BevacizumabAtaturk University
- RECRUITINGNANCT07002372Effect of Video Viewing on Intravitreal Injection ExperienceSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE2NCT06942520Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)Sierra Eye Associates